Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B

Cao,Lihua; Li,Shiwu; Dong,Jingchao; Wen,Jingkui; Ding,Lina; Ge,Yahui; Yang,Qing; Xu,Xiaoyuan; Zhuang,Hui

doi:10.3892/br.2023.1654

Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B

Authors:
- Lihua Cao
- Shiwu Li
- Jingchao Dong
- Jingkui Wen
- Lina Ding
- Yahui Ge
- Qing Yang
- Xiaoyuan Xu
- Hui Zhuang
View Affiliations

Affiliations: Liver Disease Center, Qinhuangdao Third Hospital, Qinhuangdao, Hebei 066000, P.R. China, Department of Obstetrics, Qinhuangdao Women's and Children's Hospital, Qinhuangdao, Hebei 066000, P.R. China, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, P.R. China, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, P.R. China
Published online on: August 31, 2023 https://doi.org/10.3892/br.2023.1654
Article Number: 72
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of accidental pregnancy CHB patients' reproductive age on their offspring during entecavir (ETV) antiviral therapy. A total of 112 couples were retrospectively enrolled, and they were divided into an observational and control group. A total of 53 couples who had accidental pregnancies while receiving long‑term ETV antiviral medication were recruited for the observational group. The control group consisted of 59 couples who became pregnant accidentally while receiving long‑term tenofovir disoproxil fumarate (TDF) antiviral treatment. All mothers persisted in their pregnancies in the observational group, and ETV was promptly replaced with TDF. Every mother remained pregnant and continued to use TDF in the control group. The maternal and baby safety profiles, including the prevalence of congenital disabilities, were comparable across the observational and control groups at delivery. In addition, no unusual indications or symptoms of the newborns were noted during the follow‑up intervals of 28, 48, and 96 weeks postpartum. Initiating ETV or TDF in early and middle pregnancy seems safe for mothers and infants. Important data from the present study support using ETV in early‑mid gestational accidental pregnancies and the prompt substitution of TDF antiviral medication for ETV.

View Figures

View References

1	Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact(EB/OL). https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
2	Liu J, Liang W, Jing W and Liu M: Countdown to 2030:Eliminating hepatitis B disease. Bull World Health Organ. 97:230–238. 2019.PubMed/NCBI View Article : Google Scholar
3	European Association for the Study of the Liver. EASL clinical practice guide-lines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI View Article : Google Scholar
4	Pan CQ, Hu KQ and Tsai N: Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther. 18:841–852. 2013.PubMed/NCBI View Article : Google Scholar
5	Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, et al: Early normalization of alanine aminotransferase during antiviral therapy reduces risk of hepatocellular carcinoma in HBV patients. J Clin Med. 10(1840)2021.PubMed/NCBI View Article : Google Scholar
6	Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, et al: Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroen Hepatol. 37:200–207. 2022.PubMed/NCBI View Article : Google Scholar
7	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 13:881–891. 2005.PubMed/NCBI(In Chinese).
8	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.PubMed/NCBI View Article : Google Scholar : (In Chinese).
9	Zhuang H and Weng XH: Development and management of drug resistance to nucleoside/nucleotide analogues in patients with chronic hepatitis B. Chin J Hepatol. 21:15–22. 2013.
10	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Hou JL and lai W: The Guidelines of prevention and treatment for chronic hepatitis B: A 2015 update. Zhonghua Gan Zang Bing Za Zhi. 23:888–905. 2015.(In Chinese).
11	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for chronic hepatitis B(2019 version). Zhonghua Gan Zang Bing Za Zhi. 27:938–961. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
12	European Association for the Study of the Liver. Electronic address: simpleeasloffice@easloffice.eu; European Association for the Study of the Live. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
13	Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB: Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. J Hepatol. 67:1560–1599. 2018.PubMed/NCBI View Article : Google Scholar
14	Chinese Society of Hepatology Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines of prevention and treatment for chronic hepatitis B(2022 version). Zhonghua Er Ke Za Zhi. 30:1309–1331. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).
15	World Medical Association. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 310:2191–2194. 2013.doi:10.1001/jama.2013.281053.
16	Tran TT: Management of hepatitis B in pregnancy: Weighing the options. Cleve Clin J Med. 76 (Suppl 3):S25–S29. 2009.PubMed/NCBI View Article : Google Scholar
17	Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadjo E, Preiksaitis J and Lee B: Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat. 18:468–473. 2011.PubMed/NCBI View Article : Google Scholar
18	Germer JJ, Qutub MO, Mandrekar JN, Mitchell PS and Yao JD: Quantification of hepatitis B Virus (HBV) DNA with a TaqMan HBV analyte-specific reagent following sample processing with the MagNA pure LC Instrument. J Clin Microbiol. 44:1490–1494. 2006.PubMed/NCBI View Article : Google Scholar
19	Pan CQ, Zou H, Chen Y, Zhang X, Zhang H, Li J and Duan Z: Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 11:1349–1355. 2013.PubMed/NCBI View Article : Google Scholar
20	Capital Institute of Pediatrics. The Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children. A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015. Zhonghua Er Ke Za Zhi. 56:192–199. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
21	Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, Zhang Y and Faiola F: Adverse events during pregnancy associated with entecavir and adefovir: New insights from a real-world analysis of cases reported to FDA adverse event reporting system. Front pharmacol. 12(772768)2022.PubMed/NCBI View Article : Google Scholar
22	Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S and Qing Y: Genetic evidence for genotoxic effect of entecavir, an anti-hepatitis B virus nucleotide analog. PLoS One. 11(e0147440)2016.PubMed/NCBI View Article : Google Scholar
23	The Antiretroviral Pregnancy Registry. Interim Report: 1 January 1989 through 31 January 2013 (R/OL) (2013-09-30). https://www.apregistry.com/forms/interim_report.pdf.
24	Cai H, Ma X, Li R, et al: Retrospective survey assessing pregnancy outcomes of partners of Chinese male patients with chronic hepatitis B who received long-term Entecavir treatment. Liver Int. 36 (Suppl)(S654)2014.
25	Peng J and Hou J: Current situation and management of pregnancy and anti-HBV treatment. Chin J Hepatol. 19:236–238. 2011.
26	Cao LH, Zhao PL, Liu ZM, Sun SC, Xu DB, Zhang JD and Shao MH: Efficacy and safety of nucleoside analogs on blocking father-to-infant vertical transmission of hepatitis B virus. Exp Ther Med. 9:2251–2256. 2015.PubMed/NCBI View Article : Google Scholar
27	Cao L, Li Y, Wang S, et al: Clinical research on the blocking effect of nucleoside analogue on HBV father-to-infant transmission. Chin J Exp Clin Virol. 29:251–253. 2015.
28	Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, et al: Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks postpartum: Results of the BAN Study. Antivir Ther. 19:587–595. 2014.PubMed/NCBI View Article : Google Scholar
29	Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, Blanche S, Théodoro F, Avit D, Dabis F, et al: Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'lvoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 55:1315–1317. 2011.PubMed/NCBI View Article : Google Scholar
30	Chen S, Shi Y, Yu D, et al: Influence of different state of HBV co-infections of couples on pregnancy rate, pregnancy outcomes and maternal-infant outcomes of patients treated by IVF/ICSI-ET. Chin J Nosocomiology. 31:3031–3035. 2021.